Literature DB >> 30843418

Electroacupuncture exerts an anti-migraine effect via modulation of the 5-HT7 receptor in the conscious rat.

Pei Pei1, Lu Liu2, Luo-Peng Zhao2,3, Zheng-Yang Qu2, Chu-Ying Tang4, Lin-Peng Wang2, Wenming Yang1.   

Abstract

BACKGROUND: Acupuncture has been recommended as an alternative therapy for migraine. Emerging evidence suggests that the 5-HT7 receptor (5-HT7R) plays a significant facilitatory role in descending modulation in migraine pathophysiology, and that activation of 5-HT7R in the descending pathway is involved in migraine central sensitisation.
OBJECTIVE: To investigate the ability of electroacupuncture (EA) to ameliorate central sensitisation via modulation of 5-HT7R in the descending pain pathways using a rat model of migraine induced by repetitive dural electrical stimulation (DES).
DESIGN: 64 male Sprague-Dawley rats were randomly divided into four groups: Normal group; DES group (receiving dural electrical stimulation only); DES+GB20 group (DES model group treated with EA at GB20); and DES+Sham group (DES model group treated with EA at a non-traditional (sham) acupuncture point). The presence of cutaneous allodynia was determined by measuring facial and hind-paw withdrawal latencies to electronic von-Frey. The expression of 5-HT7R in the descending pathways (periaqueductal grey, raphe magnus nucleus, and trigeminal nucleus caudalis) was assessed using immunofluorescence and Western blotting.
RESULTS: Facial and hind-paw withdrawal thresholds were significantly increased in the DES+GB20 group compared with the untreated DES group. The expression of 5-HT7R was significantly decreased in the DES+GB20 group compared with the DES group (one-way analysis of variance (ANOVA), P<0.05). No significant differences in behaviour or expression were found between the rats in the DES+Sham group and the untreated DES group (one-way ANOVA, P>0.05).
CONCLUSION: EA at GB20 may ameliorate central sensitisation in migraine by inhibiting the activation of 5-HT7 receptors in the descending pain pathway in a rat model of migraine.

Entities:  

Keywords:  5-HT7 receptor; descending pain modulatory system; dural electrical stimulation; electroacupuncture; migraine; periaqueductal grey

Mesh:

Substances:

Year:  2019        PMID: 30843418     DOI: 10.1136/acupmed-2017-011410

Source DB:  PubMed          Journal:  Acupunct Med        ISSN: 0964-5284            Impact factor:   2.267


  5 in total

1.  A Bibliometric of Trends on Acupuncture Research About Migraine: Quantitative and Qualitative Analyses.

Authors:  Kelin He; Mingjie Zhan; Xinyun Li; Lei Wu; Kang Liang; Ruijie Ma
Journal:  J Pain Res       Date:  2022-04-28       Impact factor: 2.832

Review 2.  A Comprehensive Review of Alternative Therapies for the Management of Chronic Pain Patients: Acupuncture, Tai Chi, Osteopathic Manipulative Medicine, and Chiropractic Care.

Authors:  Ivan Urits; Ruben H Schwartz; Vwaire Orhurhu; Nishita V Maganty; Brian T Reilly; Parth M Patel; Christopher Wie; Alan D Kaye; Ken F Mancuso; Aaron J Kaye; Omar Viswanath
Journal:  Adv Ther       Date:  2020-11-12       Impact factor: 3.845

3.  ST36 Acupuncture Alleviates the Inflammation of Adjuvant-Induced Arthritic Rats by Targeting Monocyte/Macrophage Modulation.

Authors:  Fuming Yang; Yinan Gong; Nannan Yu; Lin Yao; Xue Zhao; Shouhai Hong; Shenjun Wang; Bo Chen; Yuan Xu; Guangchang Pang; Hui Wang; Yongming Guo; Yanan Li; Yi Guo; Zhifang Xu
Journal:  Evid Based Complement Alternat Med       Date:  2021-02-27       Impact factor: 2.629

4.  Effect of Electroacupuncture at Fengchi on Facial Allodynia, Microglial Activation, and Microglia-Neuron Interaction in a Rat Model of Migraine.

Authors:  Pei Pei; Shengwei Cui; Shuaishuai Zhang; Sheng Hu; Linpeng Wang; Wenming Yang
Journal:  Brain Sci       Date:  2022-08-18

5.  Increasing Efficiency of Repetitive Electroacupuncture on Purine- and Acid-Induced Pain During a Three-Week Treatment Schedule.

Authors:  Jie Li; Ying Zhang; Peter Illes; Yong Tang; Patrizia Rubini
Journal:  Front Pharmacol       Date:  2021-05-10       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.